Skip to main content

Table 4 Comparison of clinical baseline data among SYNTAX II low, medium and high-risk group [n(%),M(P25-P75)]

From: Prognosis evaluation of universal acute coronary syndrome: the interplay between SYNTAX score and ApoB/ApoA1

Item Low-risk group
(0–21)
Medium-risk group
(22–28)
High-risk group
(≥29)
p
n 103156137 
GenderMale99(96.1)112(71.8)63(46)< 0.001
 Female4(3.9)44(28.2)74(54) 
In-hospital ventricular fibrillation 01(0.6)01.000
In-hospital ventricular tachycardia 1(1.0)1(0.6)1(0.7)1.000
In-hospital atrial fibrillation 1(1.0)4(2.6)4(2.9)0.637
In-hospital heart failure 12(11.7)22(14.1)36(26.3)0.004
Hypertension 53(51.5)113(72.4)85(62.0)0.003
Diabetes 18(17.5)28(17.9)33(24.1)0.324
CHD history 17(16.5)24(15.4)20(14.6)0.838
Myocardial infarction history 6(5.8)8(5.1)14(10.2)0.201
PCI history 5(4.9)6(3.8)13(9.5)0.109
Smoking history 73(70.9)85(54.5)69(50.4)0.004
Age(years old) 51.10 ± 8.2561.83 ± 7.5066.63 ± 7.82< 0.001
BMI(kg/m2) 25.79 ± 4.2524.99 ± 3.2724.91 ± 4.490.187
Ejection fraction(%) 60.95 ± 7.2661.08 ± 9.5351.81 ± 10.23< 0.001
ApoB/ApoA1High risk2(1.9)15(9.6)8(5.8)0.044
 Low risk101(98.1)141(90.4)129(94.1) 
ApoB/ApoA1 0.88(0.69–1.01)0.95(0.72–1.07)0.89(0.71–1.04)0.816
TG(mmol/l) 1.88(1.07–2.31)1.85(1.04–2.26)1.51(0.95–1.81)0.027
LDL-c(mmol/l) 3.06(2..44–3.43)3.19(2.49–3.74)3.15(2.46–3.72)0.372
Non HDL-c(mmol/l) 3.51(2.77–4.04)3.59(2.85–4.23)3.45(2.66–4.03)0.465
Hb(g/L) 142.91(134–155)141.03(131–153)138.84(128–152)0.249
PLT(×109/L) 205.64(172–232)202.76(158.25–239)201.92(164.5–233)0.937
HCT(L/L) 0.42(0.39–0.45)0.42(0.38–0.45)1.65(0.38–0.45)0.370
LM 7(6.8)12(7.7)19(13.9)0.124
PLAD 65(63.1)110(70.5)102(74.5)0.165
MLAD 50(48.5)87(55.8)78(56.9)0.397
RCX 64(62.1)115(73.7)110(80.3)< 0.001
RCA 78(75.7)134(85.9)118(86.1)0.086
RAM 2(1.9)3(1.9)0(0.0)0.266
Number of lesions treated 1.31 ± 0.581.46 ± 0.711.50 ± 0.710.024
Number of stents implanted 1.42 ± 0.811.56 ± 0.971.56 ± 1.000.244
Maximum stent diameter(mm) 3.34 ± 0.513.30 ± 0.473.28 ± 0.470.584